北京佰仁医疗科技股份有限公司 2025年第一次临时股东大会会议资 证券代码：688198 证券简称：佰仁医疗 北京佰仁医疗科技股份有限公司 2025年第一次临时股东大会会议资料 2025 年 9 月 料 | 2025年第一次临时股东大会会议须知 | 3 | | --- | --- | | 2025年第一次临时股东大会会议议程 | 6 | | 2025年第一次临时股东大会会议议案 | 8 | | 议案一：关于取消公司监事会的议案 | 8 | | 议案二：关于变更公司注册资本、修订《公司章程》并办理工商变更登记的议案 | 9 | | 议案三：关于修订《公司股东会议事规则》的议案 | 11 | | 议案四：关于修订《公司董事会议事规则》的议案 | 12 | | 议案五：关于修订《公司独立董事工作制度》的议案 | 13 | | 议案六：关于修订《公司对外担保管理制度》的议案 | 14 | | 议案七：关于修订《公司关联交易管理制度》的议案 | 15 | | 议案八：关于修订《公司利润分配管理制度》的议案 | 16 | | 议案九：关于修订《公司重大经营与投资决策管理制度》的议案 | 17 | | 议案十：关于修订《公 ...

Core Viewpoint - The company is in the early stages of production for its interventional valve products, with expected fluctuations in gross margin due to the introduction of new products and the anticipated clinical launch of the transcatheter aortic valve system next year [1] Group 1: Product Development and Market Strategy - The company aims to achieve a target of 1,000 implantations for its transcatheter aortic valve system this year, with expectations for continuous growth as hospital coverage increases and product experiences improve [1] - The company has covered 35 of the top hospitals, which account for approximately 60% of the market share, and plans to achieve full coverage by the end of the year [1] - The newly launched transcatheter valve-in-valve product is expected to have a faster market penetration compared to the transcatheter aortic valve system due to its unique positioning [1] Group 2: Regulatory Approvals and Product Pipeline - The management outlined a series of products expected to be registered this year, including "ocular biological patches," "collagen fiber fillers," and "interventional pulmonary valves," with several more planned for submission in the next four months [2] - The ePTFE pericardial membrane and collagen fiber filler-I are anticipated to receive approval in the fourth quarter, while other products will be approved by the end of this year or in the first and second quarters of next year [2] Group 3: Market Potential and Clinical Needs - The company’s vascular biological patches aim to fill a domestic gap in carotid plaque excision and vascular reconstruction surgeries, which are crucial for preventing ischemic strokes [3] - Data indicates that in 2020, approximately 460,000 deaths in China were attributed to ischemic strokes caused by carotid plaque detachment, highlighting the urgent need for surgical interventions [3] - The company is actively promoting its vascular biological patches as a standard treatment for carotid endarterectomy (CEA), which is currently underutilized in China compared to the potential patient population [3]

Core Viewpoint - The company reported strong financial performance in H1 2025, with significant revenue and profit growth, driven by successful product launches and effective cost management [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 248 million yuan, a year-on-year increase of 30.07% [1] - The net profit attributable to shareholders reached 71 million yuan, reflecting a substantial year-on-year growth of 102.90% [2] - Q2 2025 saw revenue of 148 million yuan, up 29.25% year-on-year and 47.68% quarter-on-quarter [1] - Q2 2025 net profit was 39 million yuan, a year-on-year increase of 44.75% and a quarter-on-quarter increase of 19.67% [1] Gross Margin and Cost Management - The company's gross margin for H1 2025 was 88.71%, a slight decrease of 0.82 percentage points year-on-year [1] - Q2 2025 gross margin improved to 90.54%, an increase of 1.07 percentage points year-on-year and 4.54 percentage points quarter-on-quarter [1] - The company effectively controlled costs through digitalization and strong cost management, contributing to improved gross margins [1] R&D and Product Development - The company maintained high R&D investment, with R&D expense ratio decreasing significantly due to revenue growth [2] - As of H1 2025, the company had 22 approved Class III medical devices, with 11 filling domestic market gaps [3] - 12 additional Class III medical device registration applications are expected in 2025, indicating a robust product pipeline [3] Market Position and Product Launches - The heart valve segment saw an 88.96% year-on-year increase in sales, with the TAVR product gaining significant market share [2] - The company received registration approval for TAVR in Indonesia and patent authorization in Japan [2] - The company is set to commercialize its unique "valve-in-valve" product in Q3 2025, which is expected to boost sales [4] Future Outlook - Revenue projections for 2025-2027 are set at 698 million, 1.015 billion, and 1.349 billion yuan, respectively, with net profits of 245 million, 406 million, and 555 million yuan [5] - The company is expected to benefit from increasing heart disease prevalence and expanding TAVR indications to lower-risk groups [5]

Group 1 - Bairun Medical (688198.SH) reported its semi-annual results for 2025, with 27 institutional investors holding a total of 28.2281 million A-shares, representing 20.55% of the total share capital [1] - The top ten institutional investors collectively hold 19.24% of the shares, with a decrease of 0.71 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, China Europe Times Pioneer Stock A, increased its holdings, while two funds, China Europe Value Selection Mixed A and China Europe Emerging Value One-Year Holding Mixed A, reduced their holdings by 0.96% [2] - Six new public funds were disclosed this period, including Medical Device ETF and Rongtong New Growth Mixed A [2] - One insurance fund, Ruizhong Life Insurance Co., Ltd. - Own Funds, increased its holdings slightly [2]

Group 1: Company Performance - XINWANDA reported a revenue of 26.985 billion yuan, a year-on-year increase of 12.82%, and a net profit of 856 million yuan, up 3.88% [1] - GUANGXUN TECHNOLOGY achieved a revenue of 5.243 billion yuan, a year-on-year increase of 68.59%, and a net profit of 372 million yuan, up 78.98% [1] - NORTHEAST SECURITIES posted a revenue of 2.046 billion yuan, a year-on-year increase of 31.66%, and a net profit of 431 million yuan, up 225.90% [1][2] - SHANXI COAL reported a revenue of 18.053 billion yuan, a year-on-year decrease of 16.30%, and a net profit of 1.014 billion yuan, down 48.44% [3] - SHENGTIAN NETWORK achieved a revenue of 633 million yuan, a year-on-year increase of 17.23%, and a net profit of 52.304 million yuan, up 1186.02% [4] - SANLIAN FORGING reported a revenue of 775 million yuan, a year-on-year increase of 6.86%, and a net profit of 71.335 million yuan, up 3.88% [5][6] - JIAMEI PACKAGING posted a revenue of 1.257 billion yuan, a year-on-year decrease of 8.73%, and a net profit of 19.7416 million yuan, down 65.59% [8] - ANZHENG FASHION achieved a revenue of 1.146 billion yuan, a year-on-year increase of 12.38%, and a net profit of 22.0834 million yuan, turning from a loss of 12.1096 million yuan in the previous year [9] - HUAHENG BIO reported a revenue of 1.489 billion yuan, a year-on-year increase of 46.54%, and a net profit of 115 million yuan, down 23.26% [10] - BAIREN MEDICAL achieved a revenue of 248 million yuan, a year-on-year increase of 30.07%, and a net profit of 71.4006 million yuan, up 102.90% [12] - TIANZHIHANG reported a revenue of 125 million yuan, a year-on-year increase of 114.89%, but a net loss of 57.5482 million yuan, worsening by 23.80% [14] - AIBO MEDICAL achieved a revenue of 787 million yuan, a year-on-year increase of 14.72%, and a net profit of 213 million yuan, up 2.53% [15] - ZHONGSHAN SHIPPING reported a revenue of 12.585 billion yuan, a year-on-year decrease of 4.91%, and a net profit of 2.125 billion yuan, down 14.91% [16] - SHANGHAI XINYANG achieved a revenue of 897 million yuan, a year-on-year increase of 35.67%, and a net profit of 133 million yuan, up 126.31% [17] - SHANCOAL INTERNATIONAL reported a revenue of 9.66 billion yuan, a year-on-year decrease of 31.28%, and a net profit of 655 million yuan, down 49.25% [18] - GUIDANCE reported a revenue of 935 million yuan, a year-on-year increase of 71.55%, and a net profit of 143 million yuan, turning from a loss of 48.9539 million yuan in the previous year [19] - YINGFANGWEI reported a revenue of 1.927 billion yuan, a year-on-year increase of 4.48%, but a net loss of 32.2966 million yuan, worsening from a loss of 22.4024 million yuan in the previous year [21] - CHINA COMMUNICATIONS reported a revenue of 14.665 billion yuan, a year-on-year increase of 2.91%, and a net profit of 1.621 billion yuan, up 1.34% [22] - CHINA GENERAL NUCLEAR reported a revenue of 39.167 billion yuan, a year-on-year decrease of 0.53%, and a net profit of 5.951 billion yuan, down 16.30% [23] - CHINA HEAVY TRUCK reported a revenue of 26.162 billion yuan, a year-on-year increase of 7.22%, and a net profit of 669 million yuan, up 8.10% [24] - SHENGGUANG GROUP achieved a revenue of 9.275 billion yuan, a year-on-year increase of 22.78%, and a net profit of 60.8446 million yuan, up 3.06% [25] Group 2: Dividend Proposals - XINWANDA proposed a cash dividend of 0.6 yuan per 10 shares [1] - SHANXI COAL proposed a cash dividend of 0.36 yuan per 10 shares [3] - ZHONGSHAN SHIPPING proposed a cash dividend of 0.7 yuan per 10 shares [16] - CHINA HEAVY TRUCK proposed a cash dividend of 3.15 yuan per 10 shares [24]

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 16, 2025, at 14:00 in the company's conference room located at No. 2 Huachang Road, East District, Changping Science Park, Beijing [1][4] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's shareholder meeting online voting system [1][4] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system from 9:15 to 15:00 on the day of the meeting [1][5] - Specific voting times through the trading system are from 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1][5] - Shareholders must complete identity verification to vote online for the first time [5] Meeting Agenda - The meeting will review 14 proposals that have been approved by the company's board of directors and supervisory board [3][4] - The proposals include non-cumulative voting items and matters related to business registration changes [3][13] Attendance Requirements - Shareholders registered with the China Securities Depository and Clearing Corporation Limited by the close of trading on September 9, 2025, are eligible to attend [5][6] - Registration for attendance must be completed by September 13 and September 15, 2025 [6] Proxy Voting - Shareholders can appoint proxies to attend the meeting, with specific documentation required for both individual and corporate representatives [6][12] - Proxies must present identification and authorization documents to participate in the voting process [6][12]

Group 1 - The company reported a revenue of 248 million yuan for the first half of 2025, representing a year-on-year growth of 30.07% [1] - The net profit attributable to shareholders reached 71.4 million yuan, showing a significant increase of 102.9% compared to the previous year [1] - The basic earnings per share stood at 0.52 yuan [1]

Core Viewpoint - The company Baoren Medical reported a significant increase in both revenue and net profit for the first half of the year, indicating strong financial performance and growth potential [1]. Financial Performance - The company's operating revenue for the first half of the year reached 248,028,217.88 yuan, representing a year-on-year increase of 30.07% [1]. - The net profit attributable to shareholders of the listed company was 71,400,619.61 yuan, showing a substantial year-on-year increase of 102.9% [1].

Group 1 - The core viewpoint of the report highlights the financial performance of Beijing Balancemed Medical Technology Co., Ltd. for the first half of 2025, showing significant growth in revenue and profit metrics [1][2]. - Total assets at the end of the reporting period amounted to approximately 1.45 billion RMB, reflecting a 1.62% increase compared to the end of the previous year [2]. - The company's operating income reached approximately 248 million RMB, representing a 30.07% increase year-on-year [2]. - The total profit for the period was approximately 76.4 million RMB, marking a substantial increase of 120.73% compared to the same period last year [2]. - The net profit attributable to shareholders of the listed company was approximately 61.4 million RMB, an increase of 88.55% year-on-year [2]. Group 2 - The report indicates that the company has a total of 3,426 shareholders as of the reporting period [3]. - The top ten shareholders include individuals and entities with varying ownership percentages, with the largest shareholder holding 61.21% of the shares [3][4]. - The report does not indicate any significant changes in the company's operational situation or any major events that would impact future operations [5].

Meeting Details - The third meeting of the supervisory board of Beijing Bairen Medical Technology Co., Ltd. was held on August 27, 2025, in a combined format of on-site and remote voting [1] - The meeting was convened by the chairwoman Wang Donghui, with all three supervisors present, ensuring compliance with relevant laws and the company's articles of association [1] Supervisory Board Resolutions - The supervisory board unanimously approved the proposal regarding the company's 2025 semi-annual report and its summary, confirming that the report's preparation and review procedures comply with legal regulations and internal control systems [2] - The content and format of the 2025 semi-annual report meet the requirements set by the China Securities Regulatory Commission and the Shanghai Stock Exchange, reflecting the company's true, accurate, and complete status [2] - The board also approved the proposal to abolish the supervisory board, transferring its powers to the audit committee of the board of directors, with the relevant rules being nullified [2]